| Fixed dose drug combinations–are they pharmacoeconomically sound? Findings and implications especially for lower-and middle-income countries B Godman, H McCabe, T D Leong, D Mueller, AP Martin, I Hoxha, ... Expert review of pharmacoeconomics & outcomes research 20 (1), 1-26, 2020 | 81 | 2020 |
| Antimicrobial activity, mechanism of action, and methods for stabilisation of defensins as new therapeutic agents M Amerikova, I Pencheva El-Tibi, V Maslarska, S Bozhanov, K Tachkov Biotechnology & Biotechnological Equipment 33 (1), 671-682, 2019 | 71 | 2019 |
| The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures E Moorkens, B Godman, I Huys, I Hoxha, A Malaj, S Keuerleber, ... Frontiers in pharmacology 11, 591134, 2021 | 65 | 2021 |
| Pharmacotherapeutic interventions for bipolar disorder type II: addressing multiple symptoms and approaches with a particular emphasis on strategies in lower and middle-income … B Godman, C Grobler, M Van-De-Lisle, J Wale, WB Barbosa, A Massele, ... Expert opinion on pharmacotherapy 20 (18), 2237-2255, 2019 | 50 | 2019 |
| Life expectancy and survival analysis of patients with diabetes compared to the non diabetic population in Bulgaria K Tachkov, K Mitov, Y Koleva, Z Mitkova, M Kamusheva, M Dimitrova, ... PloS one 15 (5), e0232815, 2020 | 44 | 2020 |
| Cost-of-illness studies in nine Central and Eastern European countries V Brodszky, Z Beretzky, P Baji, F Rencz, M Péntek, A Rotar, K Tachkov, ... The European Journal of Health Economics 20, 155-172, 2019 | 43 | 2019 |
| The current situation regarding long-acting insulin analogues including biosimilars among African, Asian, European, and South American countries; findings and implications for … B Godman, M Haque, T Leong, E Allocati, S Kumar, S Islam, J Charan, ... Frontiers in public health 9, 671961, 2021 | 37 | 2021 |
| Quality of life and cost study of rheumatoid arthritis therapy with biological medicines VV Boyadzieva, N Stoilov, RM Stoilov, K Tachkov, M Kamusheva, K Mitov, ... Frontiers in pharmacology 9, 794, 2018 | 31 | 2018 |
| Evaluation of the economic and social burden of chronic obstructive pulmonary disease (COPD) K Tachkov, M Kamusheva, V Pencheva, K Mitov Biotechnology & Biotechnological Equipment 31 (4), 855-861, 2017 | 28 | 2017 |
| New epidemiological, clinical and economic data for patients with acromegaly in Bulgaria M Kamusheva, S Vandeva, K Mitov, Y Rusenova, A Elenkova, ... Frontiers in Public Health 8, 147, 2020 | 19 | 2020 |
| A systematic review of collective evidences investigating the effect of diabetes monitoring systems and their application in health care M Kamusheva, K Tachkov, M Dimitrova, Z Mitkova, G García-Sáez, ... Frontiers in endocrinology 12, 636959, 2021 | 17 | 2021 |
| Impact of polypharmacy, drug-related problems, and potentially inappropriate medications in geriatric patients and its implications for Bulgaria—narrative review and meta-analysis T Krustev, P Milushewa, K Tachkov Frontiers in Public Health 10, 743138, 2022 | 16 | 2022 |
| Orphan medicinal products’ access to the Bulgarian pharmaceutical market–challenges and obstacles M Kamusheva, K Tachkov, G Petrova, A Savova, M Manova Expert Opinion on Orphan Drugs 6 (2), 95-104, 2018 | 15 | 2018 |
| Barriers to use artificial intelligence methodologies in health technology assessment in central and east European countries K Tachkov, A Zemplenyi, M Kamusheva, M Dimitrova, P Siirtola, J Pontén, ... Frontiers in Public Health 10, 921226, 2022 | 13 | 2022 |
| Prevalence of potentially inappropriate prescribing in older adults in Central and Eastern Europe: a systematic review and synthesis without meta-analysis J Brkic, D Fialova, B Okuyan, I Kummer, S Sesto, A Capiau, ... Scientific reports 12 (1), 16774, 2022 | 11 | 2022 |
| Historical overview of regulatory framework development on pricing and reimbursement of medicines in Bulgaria M Vassileva, M Kamusheva, M Manova, A Savova, K Tachkov, G Petrova Expert review of pharmacoeconomics & outcomes research 19 (6), 733-742, 2019 | 10 | 2019 |
| Economic consequences of the vaccination against hepatitis A in the Bulgarian healthcare setting M Dimitrova, G Petrova, K Tachkov, MK Bozhkova, M Kamusheva, K Mitov Biotechnology & Biotechnological Equipment 28 (2), 366-371, 2014 | 10 | 2014 |
| Recommendations for wider adoption of clinical pharmacy in Central and Eastern Europe in order to optimise pharmacotherapy and improve patient outcomes K Urbańczyk, S Guntschnig, V Antoniadis, S Falamic, T Kovacevic, ... Frontiers in pharmacology 14, 1244151, 2023 | 9 | 2023 |
| Using real-world evidence in healthcare from Western to Central and Eastern Europe: a review of existing barriers M Kamusheva, B Németh, A Zemplényi, Z Kaló, J Elvidge, M Dimitrova, ... Journal of Comparative Effectiveness Research 11 (12), 905-913, 2022 | 9 | 2022 |
| Did the introduction of biosimilars influence their prices and utilization? The case of biologic disease modifying antirheumatic drugs (bDMARD) in Bulgaria K Tachkov, Z Mitkova, V Boyadzieva, G Petrova Pharmaceuticals 14 (1), 64, 2021 | 9 | 2021 |
